|
|
| (4 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{Chembox new
| | #REDIRECT [[Telavancin hydrochloride]] |
| |ImageFile=Telavancin.png
| |
| |ImageSize=250px
| |
| |IUPACName=
| |
| |OtherNames=
| |
| |Section1= {{Chembox Identifiers
| |
| | CASNo=372151-71-8
| |
| | PubChem=3081362
| |
| | SMILES=
| |
| | MeSHName=Telavancin
| |
| }}
| |
| |Section2= {{Chembox Properties
| |
| | Formula=C<sub>80</sub>H<sub>106</sub>Cl<sub>2</sub>N<sub>11</sub>O<sub>27</sub>P
| |
| | MolarMass=1755.63 g/mol
| |
| | Appearance=
| |
| | Density=
| |
| | MeltingPt=
| |
| | BoilingPt=
| |
| | Solubility=
| |
| }}
| |
| |Section3= {{Chembox Hazards
| |
| | MainHazards=
| |
| | FlashPt=
| |
| | Autoignition=
| |
| }}
| |
| }}
| |
| {{SI}}
| |
| | |
| | |
| '''Telavancin''' is a [[bactericidal]] [[lipoglycopeptide]] under trial for use in [[MRSA]] or other [[Gram-positive]] infections.
| |
| | |
| On October 19, 2007, the [[United States|US]] [[Food and Drug Administration]] issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. <ref>{{cite web |url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |format= |work= }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| ==External links==
| |
| * [http://www.theravance.com Theravance, Inc.]
| |
| | |
| {{Other antibacterials}}
| |
| | |
| [[Category:Antibiotics]]
| |
| | |
| | |
| | |
| {{WH}}
| |
| {{WikiDoc Sources}}
| |